Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers

Summary

Platelet activation, commonly found in lung cancer patients, may cause the release of angiogenic factors, such as vascular endothelial growth factor (VEGF-A). The present study was designed to investigate whether plasma VEGF-A levels were associated to different stages of non-small cell lung cancer (NSCLC). Moreover, sP-selectin, prothrombin fragment 1+2 (F1+2),thrombin-antithrombin III complex (TATc) and D-dimer levels were measured to test the hypothesis of an involvement of platelet and coagulation activation in tumor angiogenesis. VEGF-A, sP-selectin, F1+2, TATc and D-dimer levels were elevated in 65 patients with NSCLC, particularly in metastatic patients. sP-selectin (p <0.003) and F1+2 (p <0.005) levels were independently associated to VEGF-A. In addition, patients with positive levels of both sP-selectin and F1+2 had the highest levels of VEGF-A. In conclusion, our findings support the hypothesis that thrombin generation might induce platelet activation and VEGF-A release in NSCLC.

Keywords

Lung cancer - thrombin generation - soluble P-selectin - angiogene-sis - vascular endothelial growth factor

• References

• 1 Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev 2001; 15: 61-7.
• 2 Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 1997; 94: 663-8.
• 3 Verheul HM, Jorna AS, Hoekman K, Broxter-man HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000; 96: 4216-21.
• 4 Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyper-permeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
• 5 Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12: 303-24.
• 6 Mattern J, Koomagi R, Volm M. Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density. Anticancer Res 1997; 17: 2249-52.
• 7 Volm M, Koomagi R, Mattern J. PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 1999; 19: 651-5.
• 8 Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997; 74: 64-8.
• 9 Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S, Edgington TS, Kudryk B, Kreutzer DL, Rickles FR. Activation of coagulation and angiogenesis in cancer: immunohis-tochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152: 399-411.
• 10 Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-90.
• 11 Milroy R, Douglas JT, Campbell J, Carter R, Lowe GD, Banham SW. Abnormal haemosta-sis in small cell lung cancer. Thorax 1988; 43: 978-81.
• 12 Prisco D, Paniccia R, Coppo M, Filippini M, Francalanci I, Brunelli T, Comeglio P, Abbate R. Platelet activation and platelet lipid composition in pulmonary cancer. Prostaglandins Leukot Essent Fatty Acids 1995; 53: 65-8.
• 13 Blann AD, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation?. Atherosclerosis 1997; 128: 135-8.
• 14 Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P, Lip GY. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Wille-brand factor. Blood Coagul Fibrinolysis 2001; 12: 43-50.
• 15 Schadendorf D, Diehl S, Zuberbier T, Schadendorf C, Henz BM. Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology 1996; 192: 89-93.
• 16 Haznedaroglu IC, Benekli M, Ozcebe O, Savas MC, Gullu IH, Dundar SV, Kirazli S. Serum L-selectin and P-selectin levels in lymphomas. Haematologia 2000; 30: 27-30.
• 17 Roselli M, Mineo TC, Martini F, Mariotti S, Ambrogi V, Spila A, D’Alessandro R, Basili S, Guadagni F, Ferroni P. Serum Concentrations of Soluble Selectins in Patients with Lung Cancer. Int J Biol Markers 2002; 17: 56-62.
• 18 Iversen LH, Okholm M, Thorlacius-Ussing O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease. A preliminary study. Thromb Haemost 1996; 76: 523-8.
• 19 Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998; 115: 1007-14.
• 20 Brattstrom D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O, Wagenius G. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 1998; 18: 1123-7.
• 21 Tamura M, Ohta Y, Kajita T, Kimura K, Go T, Oda M, Nakamura H, Watanabe G. Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. Oncol Rep 2001; 8: 1097-102.
• 22 Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956-64.
• 23 Dittardi R, Meo S, Fabris F, Gasparini G, Con-tri D, Medici M, Gion M. Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers 2001; 16: 87-96.
• 24 Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001; 47: 617-23.
• 25 Berger G, Hartwell DW, Wagner DD. P-selectin and platelet clearance. Blood 1998; 92: 4446-52.
• 26 Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK, Pinedo HM. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000; 6: 166-71.
• 27 Pinedo HM, Verheul HM, D’Amato RJ, Folkman J. Involvement of platelets in tumor angiogenesis?. Lancet 1998; 352: 1775-7.
• 28 Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Haemost 1999; 25: 167-72.
• 29 Honn KV, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Haemost 1992; 18: 390-413.
• 30 Cavanaugh PG, Sloane BF, Honn KV. Role of the coagulation system in tumor cell-induced platelet aggregation and metastasis. Haemostasis 1988; 18: 37-46.
• 31 Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Tsutsui K, Suzuki S. Coagulation-fibrinolysis system and markers of collagen metabolism in lung cancer. Cancer 1992; 70: 2631-6.
• 32 Seitz R, Rappe N, Kraus M, Immel A, Wolf M, Maasberg M, Egbring R, Pfab R, Havemann K. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumor stage and prognosis. Blood Coagul Fibrinolysis 1993; 4: 249-54.
• 33 Kakkar AK, Williamson RC. Thromboprophylaxis in malignant disease. Br J Surg 1995; 82: 724-5.
• 34 Salgado R, Benoy I, Bogers J, Weytjens R, Vermeulen P, Dirix L, Van Marck E. Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study. Angio-genesis 2001; 4: 37-43.
• 35 Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 10-23.